Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$2.74 - $13.43 $101,654 - $498,253
37,100 Added 42.94%
123,500 $377,000
Q1 2022

May 16, 2022

SELL
$8.96 - $13.51 $74,368 - $112,133
-8,300 Reduced 8.76%
86,400 $1.17 Million
Q4 2021

Feb 14, 2022

BUY
$9.17 - $16.39 $868,399 - $1.55 Million
94,700 New
94,700 $1.23 Million

Others Institutions Holding ATHA

About Athira Pharma, Inc.


  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $20.4M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.